Organovo Holdings Dividends and Buybacks

Dividend criteria checks 0/6

Organovo Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-136.1%

Buyback Yield

Total Shareholder Yield	-136.1%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ONVO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONVO's dividend payments have been increasing.

Dividend Yield vs Market

Organovo Holdings Dividend Yield vs Market

How does ONVO dividend yield compare to the market?
Segment	Dividend Yield
Company (ONVO)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (ONVO) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate ONVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONVO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ONVO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ONVO has not reported any payouts.

Organovo Holdings Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Organovo Holdings, Inc. Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$0.75 loss

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies